Alembic Pharmaceuticals Limited has informed stock exchanges about the superannuation of Mr. Ashok Pandya, who served as Resident Director. The pharmaceutical company filed the mandatory disclosure on January 31st, 2026, notifying both BSE and NSE about this senior management change.

Management Transition Details

The company submitted the intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events and information. The notification was signed by Company Secretary Manisha Saraf and includes detailed annexures as required by regulatory guidelines.

Superannuation Specifics

According to the regulatory filing, the management change occurred due to superannuation, with specific timing and procedural details outlined in the company's disclosure.

Regulatory Compliance

The disclosure demonstrates Alembic Pharmaceuticals' adherence to corporate governance requirements and transparency standards. The company provided comprehensive documentation including annexures as mandated by SEBI regulations for senior management personnel changes.

The notification was addressed to both major Indian stock exchanges where the company's shares are listed, ensuring complete regulatory compliance and stakeholder transparency regarding this organizational transition.

Alembic Pharmaceuticals Limited has announced a board meeting scheduled for February 5, 2026, to review and approve its unaudited financial results for the third quarter of fiscal year 2026. The meeting will focus on the financial performance for the quarter and nine months ended December 31, 2025.

Board Meeting Details

The pharmaceutical company has formally notified both the Bombay Stock Exchange and National Stock Exchange of India about the upcoming board meeting. The notification, dated January 20, 2026, was signed by Company Secretary Manisha Saraf and submitted to fulfill regulatory compliance requirements under applicable regulations.

Trading Window Restrictions

In accordance with the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, Alembic Pharmaceuticals has implemented trading window restrictions. The trading window for dealing in the company's securities was closed effective January 1, 2026.

The company has specified that the trading window will reopen 48 hours after the official declaration of the financial results. This measure ensures compliance with insider trading regulations and maintains market integrity during the financial results announcement period.

Regulatory Compliance

The board meeting announcement demonstrates Alembic Pharmaceuticals' adherence to stock exchange regulations and corporate governance standards. The company has provided advance notice to both major Indian stock exchanges, allowing investors and market participants to prepare for the upcoming financial disclosure.

The pharmaceutical company's registered office is located at Alembic Road, Vadodara, and it maintains regular communication with stakeholders through its official website and designated email channels for investor relations and corporate communications.